Shaun R. Bagai

Mr. Bagai brings over 21 years of medical technology expertise with a proven track record in leadership roles in clinical research, physician training, sales, marketing, and market development. He has successfully launched novel technologies into regional and global marketplaces in large corporations as well as growth-phase companies. He was instrumental in developing the European market for renal denervation for the treatment of hypertension which led to the acquisition of the first renal denervation company, Ardian, Inc., by Medtronic in 2011 for over $850M. Prior to joining RenovoRx, Mr. Bagai led global market development for HeartFlow, Inc., which included directing Japanese market research, regulatory/payer collaboration, and Key Opinion Leader development to create value resulting in the creation of HeartFlow-Japan. Prior to leaving HeartFlow, he also successfully orchestrated their largest clinical trial and contracted HeartFlow’s first global customers. Mr. Bagai is a graduate from the University of California, Santa Barbara with a B. Sc. in Biology/Pre-med.